Kestra Medical Technologies (NASDAQ:KMTS) Stock Price Up 4.4% - Time to Buy?

Key Points

• Kestra Medical Technologies (NASDAQ:KMTS) saw a stock price increase of 4.4%, trading last at $24.30, following a decline in average daily trading volume.
• Analyst reports indicate a mixed outlook, with Wells Fargo reducing its price target from $28 to $27 and Wall Street Zen downgrading its rating from "hold" to "sell."
• The company's recent quarterly earnings exceeded analyst expectations, reporting a loss of $0.46 EPS against an estimate of $0.66, with revenues reaching $19.37 million.

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) rose 4.4% during mid-day trading on Friday . The company traded as high as $24.41 and last traded at $24.30. Approximately 217,447 shares were traded during trading, a decline of 22% from the average daily volume of 278,086 shares. The stock had previously closed at $23.27.

Wall Street Analysts Forecast Growth

KMTS has been the subject of a number of analyst reports. Wells Fargo & Company cut their price target on Kestra Medical Technologies from $28.00 to $27.00 and set an "overweight" rating for the company in a research note on Thursday, July 17th. Wall Street Zen downgraded Kestra Medical Technologies from a "hold" rating to a "sell" rating in a research note on Sunday, September 28th. Finally, Weiss Ratings reiterated a "sell (d)" rating on shares of Kestra Medical Technologies in a research note on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $27.33.

Kestra Medical Technologies Trading Up 4.4%

The company has a quick ratio of 6.84, a current ratio of 6.84 and a debt-to-equity ratio of 0.23. The business's fifty day moving average is $20.33 and its 200 day moving average is $20.15.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last posted its quarterly earnings results on Thursday, September 11th. The company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.66) by $0.20. The company had revenue of $19.37 million during the quarter, compared to the consensus estimate of $17.68 million. Kestra Medical Technologies has set its FY 2026 guidance at EPS.

Institutional Investors Weigh In On Kestra Medical Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the business. Quarry LP bought a new stake in Kestra Medical Technologies during the 1st quarter valued at $33,000. Police & Firemen s Retirement System of New Jersey bought a new stake in Kestra Medical Technologies during the 2nd quarter valued at $54,000. New York State Common Retirement Fund bought a new stake in Kestra Medical Technologies during the 2nd quarter valued at $93,000. Walleye Capital LLC bought a new stake in Kestra Medical Technologies during the 2nd quarter valued at $166,000. Finally, Rhumbline Advisers bought a new stake in Kestra Medical Technologies during the 2nd quarter valued at $200,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.